Microalbuminuria, Other Markers of Nephropathy and Biochemical Derangementsin Type 2 Diabetes Mellitus: Relationships and Determinants
Overview
Affiliations
Background: Microalbuminuria is an early indicator of Diabetic nephropathy and cerebrovascular disease.
Objective: To evaluate relationships between microalbuminuria and other predictors of morbidity and mortality in type 2 DM.
Methods: Fifty type 2 diabetic subjects were recruited each for three groups separated by disease durations. Thirty non-diabetic subjects were recruited to control each group. Urine albumin-to-creatinine ratio (ACR) was estimated. Fasting plasma glucose (FPG), serum creatinine, urea, total cholesterol (TC), triglycerides (TG), high-and low density lipoprotein (HDL, LDL) were measured.
Results: The diabetics with longest disease duration of >10 years were the oldest (65.86±1.71), had highest systolic BP (147.12±3.39mmHg) and least BMI (27.20±0.71Kg/m); they had poorest lipid control (TC:5.54±0.26mmol/L), though with the least TG (0.97±0.09mmol/L); they also had the most severe microalbuminuria (33.63±8.03g/L) and ACR (65.85±10.38mg/gm). Patients with diabetes of 5-10 years had the poorest glycaemic control:FPG-7.82±0.47mmol/L; HbA1c-13.09±0.74%). Significant negative correlations exist between microalbuminuria, HBA1c(r=-2.28, p=0.028) and serum creatinine(r=-2.11, p=0.042) in patients with 5-10 years disease; a positive correlation between the ACR and TC(r=1.00,p<0.01) in those with >10 years disease. In multivariate analysis, independent predictors of microalbuminuria were disease duration (OR 2.2, p< 0.001); HBA1c (OR 7.3, p=0.02); LDL/HDL ratio (OR 13.4, p< 0.001).
Conclusion: The severity and progression of albuminuria are associated with longer duration of diabetes and poor glycaemic control. Significant relationships exist between ACR and HBA1c, TC, HDL-C, TG, creatinine. Disease duration, ethnicity, HBA1c, TC, TG, HDL-C and LDL/HDL ratio are independent predictors of albuminuria.
Funding: None declared.
Role of urinary trace elements in diabetic kidney disease: a cross-sectional analysis.
Gao T, Lv J, Lu L, Guo L, Tang W, Shao F BMJ Open Diabetes Res Care. 2024; 12(6.
PMID: 39706673 PMC: 11667472. DOI: 10.1136/bmjdrc-2024-004454.
The therapeutic effect of mesenchymal stem cells in diabetic kidney disease.
Habiba U, Khan N, Greene D, Shamim S, Umer A J Mol Med (Berl). 2024; 102(4):537-570.
PMID: 38418620 PMC: 10963471. DOI: 10.1007/s00109-024-02432-w.
Advances in Traditional Chinese Medicine research in diabetic kidney disease treatment.
Shen S, Zhong H, Zhou X, Li G, Zhang C, Zhu Y Pharm Biol. 2024; 62(1):222-232.
PMID: 38357845 PMC: 10877659. DOI: 10.1080/13880209.2024.2314705.
Mathan Kumar S, Essakky S, Rajasulochana S, Kar S, Sivanatham P, Anandraj J Int J Technol Assess Health Care. 2023; 39(1):e66.
PMID: 37960938 PMC: 11579677. DOI: 10.1017/S0266462323002623.
Tekalign T, Guta M, Awoke N, Chichiabellu T, Meskele M, Anteneh G Int J Nephrol Renovasc Dis. 2023; 16:163-172.
PMID: 37332621 PMC: 10275322. DOI: 10.2147/IJNRD.S396574.